The SKILL card test in optic neuritis: Experience of the optic neuritis treatment trial

Optic Neuritis Study Group

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Objectives To assess the value of the Smith-Kettlewell Institute Low Luminance (SKILL) Card test, designed to measure vision at reduced contrast and luminance, among patients with previous optic neuritis. Materials and Methods The SKILL Card test was administered to 295 patients participating in the Optic Neuritis Treatment Trial (ONTT) follow-up study, concurrent with measurement of visual acuity, visual field, contrast sensitivity, and color vision. Health-related quality of life (HRQL) was also assessed in a subset of patients using the National Eye Institute Visual Function Questionnaire and an ONTT-developed questionnaire. Results The SKILL Card difference score (high-contrast acuity score minus low-contrast acuity score) was only weakly associated with the other measures of vision function (rs absolute range, 0.05-0.31) and with the HRQL measures (rs absolute range, 0.02-0.15). In contrast, the light and dark component scores of the SKILL Card test had higher associations with the other vision measures (rs absolute range, 0.27-0.54) and with the HRQL measures (rs absolute range, 0.10-0.40). Conclusions The SKILL Card difference score is not a meaningful measure for patients with optic neuritis; however, the test appears to have clinical usefulness as a method to measure high-contrast and low-contrast acuity.

Original languageEnglish (US)
Pages (from-to)124-131
Number of pages8
JournalJournal of Neuro-Ophthalmology
Volume21
Issue number2
StatePublished - 2001
Externally publishedYes

Keywords

  • Health-related quality of life
  • High-contrast visual acuity
  • Low-contrast visual acuity
  • Optic neuritis
  • SKILL card

ASJC Scopus subject areas

  • Ophthalmology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'The SKILL card test in optic neuritis: Experience of the optic neuritis treatment trial'. Together they form a unique fingerprint.

Cite this